343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs
The Readout Loud
Intro
This chapter explores recent trends in biotech investments, noting a significant rise in new venture capital firms and diverse founder demographics. It also hints at forthcoming discussions on critical industry changes, including the FDA's challenges and Bluebird Bio's private equity deal.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
